Financial News

Date Title and Summary Additional Formats
Toggle Summary ViewRay's MRIdian to be Featured at Leading European Radiation Oncology Meeting
26 Clinical Presentations and Posters Highlight Benefits of MRI-Guided Radiation Therapy Across Applications and Growing Use of Adaptive Therapy CLEVELAND , April 23, 2019 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) announced today that the company's MRIdian MRI-guided radiation therapy system
Toggle Summary ViewRay Partners with Leading Canadian Distributor to Bring MRI-guided Radiation Therapy to Canada
Minogue Medical to Serve as Exclusive Canadian Distributor for ViewRay's MRIdian System CLEVELAND , April 18, 2019 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) announced today that the company has partnered with Minogue Medical Inc. , a leading Canadian distributor of surgical devices, operating
Toggle Summary ViewRay Partners with Largest Independent Distributor in Australia and New Zealand to Bring Benefits of MRI-Guided Radiation Therapy to the Region
Device Technologies Australia to Help Expand Global MRIdian Adoption CLEVELAND , April 17, 2019 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) and Device Technologies Australia Pty Ltd (Device Technologies) announced today a partnership in which Device Technologies, the largest independent
Toggle Summary ViewRay Announces Conference Call and Webcast of First Quarter 2019 Financial Results to be Held After Market on May 2, 2019
CLEVELAND , April 11, 2019 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its first quarter 2019 financial results. ViewRay will hold a conference call to discuss results on Thursday, May 2, 2019 at 4:30 p.m. ET / 1:30 p.m. PT .
Toggle Summary ViewRay Announces Publication of Retrospective Study on MR-guided Radiation Treatment for Locally Advanced Pancreatic Cancer
High-Dose Radiation Therapy Enabled by MRIdian's Daily On-table Adaptation and Gating Beam Control Results in Excellent Retrospective Local Tumor Control, Low Toxicity, and Outstanding Overall Survival versus Non-adaptive Treatment CLEVELAND , April 11, 2019 /PRNewswire/ --   ViewRay, Inc.
Toggle Summary ViewRay Reports Fourth Quarter and Full Year 2018 Results
CLEVELAND , March 14, 2019 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the fourth quarter and full year ended December 31, 2018 . Full Year 2018 Highlights: Total revenue of $81.0 million , primarily from 13 revenue units and 2 system upgrades, compared to
Toggle Summary ViewRay Announces FDA 510(k) Clearance for Advancements in MRI and Functional Imaging Technologies for MRIdian MRI-Guided Radiation Therapy System
Proprietary Technology from ViewRay Enables Imaging and Treatment Enhancements CLEVELAND , Feb. 21, 2019 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY), announced today that the company received 510(k) clearance from the U.S. Food and Drug Administration ( FDA ) to market new soft tissue
Toggle Summary ViewRay Announces Conference Call and Webcast of Fourth Quarter and Full Year 2018 Financial Results to be Held After Market on March 14, 2019
CLEVELAND , Feb. 14, 2019 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its fourth quarter and full year 2018 financial results. ViewRay will hold a conference call to discuss results on Thursday March 14, 2019 at 4:30 p.m. ET / 1:30 p.m. PT .
Toggle Summary World's First MRIdian Center Celebrates Five Years of MRI-Guided Radiation Treatments
Siteman Cancer Center Advances Precision Cancer Care through Presentations, Peer-Reviewed Publications and Pioneering Clinical Experience on its MRIdian Systems CLEVELAND , Jan. 22, 2019 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) announced today the five-year anniversary of patient treatments
Toggle Summary ViewRay Announces Preliminary Fourth Quarter and Fiscal Year 2018 Results
CLEVELAND , Jan. 7, 2019 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) today announced preliminary results for the fourth quarter and full fiscal year ended December 31, 2018 . The preliminary results have not been audited and are subject to change. Selected Fourth Quarter and Full Year 2018
Toggle Summary ViewRay Announces First Patient Enrolled in Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) Trial for Locally Advanced Pancreatic Cancer
Study to Explore Clinical Benefits of Precise, High Dose Radiation Therapy Enabled by MRIdian's MR-guidance Combined with Daily On-table Adaptation in Pancreatic Cancer CLEVELAND , Jan. 4, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today the enrollment of the first patient in the

Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.

E-mail Alerts

Alerts are e-mailed to you whenever certain new company information is posted to this site. Sign-up Now!
Click here for E-mail Alerts

Transfer Agent
American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
(800) 937-5449
Website: www.amstock.com
Email: info@amstock.com

In Need of Customer Support? Contact

  Language Select